NCT02401230View on ClinicalTrials.gov

PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIV

PHASE4CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

January 25, 2017

Study Completion Date

January 25, 2017

Conditions
HIV
Interventions
DRUG

Truvada

Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.

DEVICE

Gel lubricant

Five ml of an over the counter sexual lubricant will be dispensed using an applicator.

Trial Locations (1)

30030

The Hope Clinic of of Emory University, Decatur

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

lead

Emory University

OTHER

NCT02401230 - PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIV | Biotech Hunter | Biotech Hunter